This policy applies to the following:

 is policy applies to the					
Standard Control	Managed Medicaid	ACSF Chart	1	Medical Benefit	Medicare Part B
(SF)	Template (MMT)	(ACSFC)	*		
Standard Control -	Marketplace	SF Chart	1	Medical: Advanced	Medicare Part B:
Choice (SCCF)	(MF)	(SFC)	<b>,</b>	Biosimilars First	Biosimilars First
Preferred Drug Plan	Aetna Health	VF Chart		Medical Benefit:	Medicare Part B:
Design (PDPD)	Exchange (AHE)	(VFC)		Managed Medicaid	Advanced
		1 ` ´			Biosimilars First
Advanced Control	IVL	New to Market		Medical Benefit:	
Specialty (ACSF)		(NTM)		Add-on	
Advanced Control	Value (VF)				
Specialty - Choice	` ′				
(ACSCF)					

Reference #
5057-D

# EXCEPTIONS CRITERIA RETINAL DISORDERS

PRIMARY PREFERRED PRODUCT: AVASTIN

SECONDARY PREFERRED PRODUCTS: BYOOVIZ, CIMERLI

### **POLICY**

This policy informs prescribers of preferred products and provides an exception process for targeted products through prior authorization.

#### I. PLAN DESIGN SUMMARY

This program applies to the retinal disorder products specified in this policy. Coverage for targeted products is provided based on clinical circumstances that would exclude the use of the preferred products and may be based on previous use of a product. The coverage review process will ascertain situations where a clinical exception can be made. This program applies to all members requesting treatment with Lucentis who have not tried a secondary preferred product. This program applies to members who are new to treatment with Byooviz, Cimerli, Eylea, and Vabysmo for the first time.

Each referral is reviewed based on all utilization management (UM) programs implemented for the client.

**Table. Retinal Disorder products** 

	Product(s)	
Primary Preferred*	Avastin (bevacizumab)	
Secondary Preferred*	Byooviz (ranibizumab-nuna)	
	Cimerli (ranibizumab-eqrn)	
Targeted	Eylea (aflibercept)	
	Lucentis (ranibizumab)	
	Vabysmo (faricimab-svoa)	

<sup>\*:</sup> Medications considered formulary or preferred on your plan may still require a clinical prior authorization review.

# II. EXCEPTION CRITERIA

# A. Byooviz, Cimerli

Coverage for the targeted products is provided when any of the following criteria are met:

Specialty Exceptions Retinal Disorders Medical-Medical ABF 5057-D P2024.docx

© 2024 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.



This policy applies to the following:

S poncy applies to the		A COT OL		M. C. ID. C.	M. C D D
Standard Control	Managed Medicaid	ACSF Chart	1	Medical Benefit	Medicare Part B
(SF)	Template (MMT)	(ACSFC)			
Standard Control -	Marketplace	SF Chart	./	Medical: Advanced	Medicare Part B:
Choice (SCCF)	(MF)	(SFC)	<b>v</b>	Biosimilars First	Biosimilars First
Preferred Drug Plan	Aetna Health	VF Chart		Medical Benefit:	Medicare Part B:
Design (PDPD)	Exchange (AHE)	(VFC)		Managed Medicaid	Advanced
, ,		` ′			Biosimilars First
Advanced Control	IVL	New to Market		Medical Benefit:	
Specialty (ACSF)		(NTM)		Add-on	
Advanced Control	Value (VF)				
Specialty - Choice	·				
(ACSCF)					

Reference #	
5057-D	

- 1. Member is currently receiving treatment with a targeted product, Byooviz or Cimerli, excluding when the requested targeted product is obtained via samples or via manufacturer's patient assistance programs.
- 2. Member has had a documented inadequate response or intolerable adverse event with the primary preferred product, Avastin.

## B. Eylea

Coverage for the targeted product is provided when any of the following criteria are met:

- 1. Member is currently receiving treatment with the targeted product, Eylea, excluding when the requested targeted product is obtained via samples or via manufacturer's patient assistance programs.
- 2. Member has a diagnosis of retinopathy of prematurity.
- 3. Member has a documented inadequate response or intolerable adverse event with the primary preferred product, Avastin, and at least one of the secondary preferred products, Byooviz or Cimerli.

#### C. Lucentis

Coverage for the targeted product is provided when all of the following criteria are met:

- 1. Member meets either of the following criteria:
  - A. Member is currently receiving treatment with the targeted product, Lucentis, excluding when the requested targeted product is obtained via samples or via manufacturer's patient assistance programs.
  - B. Member has had a documented inadequate response or intolerable adverse event with the primary preferred product, Avastin.
- 2. Member has a documented intolerable adverse event to both of the secondary preferred products, Byooviz and Cimerli, and the adverse event was not an expected adverse event attributed to the active ingredient as described in the prescribing information (i.e., known adverse reaction for both the reference product and biosimilar products).

#### D. Vabysmo

Coverage for the targeted product is provided when any of the following criteria are met:

- 1. Member is currently receiving treatment with the targeted product, Vabysmo, excluding when the requested targeted product is obtained as samples or via manufacturer's patient assistance programs.
- 2. Member has a documented inadequate response or intolerable adverse event with the primary preferred product, Avastin, and at least one of the secondary preferred products, Byooviz or Cimerli.

## **REFERENCES**

- 1. Avastin [package insert]. South San Francisco, CA: Genentech, Inc.; December 2020.
- 2. Byooviz (ranibizumab) [package insert]. Cambridge, MA: Biogen Inc; June 2022.
- 3. Cimerli [package insert]. Redwood City, CA: Coherus BioSciences, Inc.; November 2022.
- 4. Eylea [package insert]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc.; August 2022.

Specialty Exceptions Retinal Disorders Medical-Medical ABF 5057-D P2024.docx

© 2024 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.



This policy applies to the following:

Standard Control (SF)	Managed Medicaid Template (MMT)	ACSF Chart (ACSFC)	✓	Medical Benefit	Medicare Part B
Standard Control – Choice (SCCF)	Marketplace (MF)	SF Chart (SFC)	✓	Medical: Advanced Biosimilars First	Medicare Part B: Biosimilars First
Preferred Drug Plan Design (PDPD)	Aetna Health Exchange (AHE)	VF Chart (VFC)		Medical Benefit: Managed Medicaid	Medicare Part B: Advanced Biosimilars First
Advanced Control Specialty (ACSF)	IVL	New to Market (NTM)		Medical Benefit: Add-on	
Advanced Control Specialty – Choice (ACSCF)	Value (VF)				

Reference #
5057-D

- 5. Lucentis [package insert]. San Francisco, CA: Genentech, Inc.; March 2018.
- 6. Vabysmo [package insert]. San Francisco, CA: Genentech, Inc.; January 2023.

Specialty Exceptions Retinal Disorders Medical-Medical ABF 5057-D P2024.docx

pharmaceutical manufacturers that are not affiliated with CVS Caremark.

© 2024 CVS Caremark. All rights reserved.





This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of